Catalogue

Background
GAPDH is constitutively expressed at high levels in almost all tissues and cell lines making it ideal for use as a loading control marker in immunoblots. Independent of its glycolytic activity it is also involved in membrane trafficking in the early secretory pathway.

Source

Immunogen: Synthetic peptide derived from the human GAPDH alpha protein.

Product

Product Form: Affinity Purified

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Antigen Immunoaffiinity Purification

Concentration: See vial for concentration

Applications
Antibody can be used for Western Blotting (1:400 dilution) and immunohistochemistry (2-10 µg/ml). Optimal concentration should be evaluated by serial dilutions.

Functional Analysis: Western Blotting

Positive Control: Human liver tissue, human testis

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Nakajima, H., et al. 'GAPDH aggregate formation participates in oxidative stress-induced cell death.' J. Biol. Chem. 2009:Epub 2. Nahlik, K.W., et al. 'Modulation of GAPDH expression and cellular localization after vaccinia virus infection of human adherent monocytes.' Acta Biochim. Pol. 2003: 50(3); 667-676.

Protein Reference(s)

Database Name: UniProt

Accession Number: P04406

Species Accession: Human

Safety Datasheet(s) for this product: